Stay updated on Ferumoxytol MRI in Glioblastoma Response Clinical Trial
Sign up to get notified when there's something new on the Ferumoxytol MRI in Glioblastoma Response Clinical Trial page.

Latest updates to the Ferumoxytol MRI in Glioblastoma Response Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe clinical trial record for a Phase 2 study of ferumoxytol MRI and pembrolizumab in glioblastoma is now displayed, including study design, eligibility criteria, outcomes, and posted results. The study is listed as terminated and no longer recruiting.SummaryDifference57%

- Check21 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedA notice announces updates to NIH websites and says the agency is transitioning from the term “Artificial Intelligence” to “Super Intelligence” in some content.SummaryDifference1%

- Check35 days agoChange DetectedThe ClinicalTrials.gov footer revision advances from v3.7.1 to v3.7.2, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site footer revision identifier changed from `v3.7.0` to `v3.7.1`; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check63 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study content, indicating access is blocked. The screen shows a 403 message and related navigation/footer elements reflecting an error state.SummaryDifference20%

Stay in the know with updates to Ferumoxytol MRI in Glioblastoma Response Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ferumoxytol MRI in Glioblastoma Response Clinical Trial page.